MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

INKT Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

MiNK Therapeutics, Inc.NASDAQ: INKT

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital dips below year-ago levels

Q1 FY2026 change in working capital of $343.32K fell 41.9% year over year, behind the +607.3% change in trailing-twelve-month change in working capital. Sequentially, it fell 26.9% from the prior quarter. Over 3 fiscal years it compounded at -27.9% a year.

Context

  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -41.9% toward the trailing-twelve-month pace of +607.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$343.32K-26.9% QoQ
Last fiscal yearDec 2025
$3.29M+615.4% YoY
LTMMar 2026
$3.04M+607.3% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.9%——
1 year+615.4%——
3-year CAGR-27.9%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
3.29M USD
Year-over-year change
+615.4%
4-year CAGR
-3.1%

Change in Working Capital vs competitors

How INKT compares with its peers on the latest reported figures

  • INKT's LTM Mar 2026 change in working capital of $3.04M is the 5th largest of the 9 companies compared; the peer median is $44.68K.
  • Its year-over-year change of +607.3% is the 3rd highest of 9, against a peer median of +36.9%.
  • Over three fiscal years its annual growth of -27.9% compares with a peer median of +26.3%.
INKT Competitors Peer median
Change in Working Capital for INKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VTVTvTv Therapeutics Inc.LTM Mar 2026$18.69M +942.0%-29.4%50.7%
OSTXOS Therapies IncorporatedLTM Mar 2026$13.32M +2303.6%+112.6%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$6.94M +103.5%—2082.3%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$5.38M -1724.8%—25.6%
INKTMiNK Therapeutics, Inc.LTM Mar 2026$3.04M +607.3%-27.9%—
EQEquillium, Inc.LTM Mar 2026$2.16M -139.0%——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$1.74M -42.1%+26.3%75.9%
GANXGain Therapeutics, Inc.LTM Mar 2026$939.36K -29.8%——
SPRBSpruce Biosciences, Inc.LTM Mar 2026$850K +131.0%——
Peer median (excluding INKT) $44.68K+36.9%+26.3%63.3%

Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Depreciation & Amortization77.96K121.75K204.62K215.44K181.75K
Deferred Income Tax00000
Stock-Based Compensation1.74M3.03M3.86M1.81M2.67M
Change in Working Capital3.74M8.77M2.9M459.73K3.29M
Accounts Receivables00000
Inventory00000
Accounts Payables(152.04K)2.66M(1.92M)(1.18M)689.71K
Other Working Capital3.89M6.11M4.81M1.64M2.6M
Other Non-Cash Items11.83M(2.79M)(266.78K)(1.26M)424.63K
Operating Cash Flow(12.83M)(18.87M)(15.76M)(9.56M)(5.93M)
Capital Expenditures(248.98K)(250.05K)(73.56K)(4)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(248.98K)(250.05K)(73.56K)00
Debt Repayment9.46M005M0
Common Stock Issued39.8M005.8M14.9M
Common Stock Repurchased0(157.19K)(477.64K)00
Dividends Paid00000
Other Financing Activities1501.6K70.47K19.99K(173.35K)
Financing Cash Flow49.26M(155.6K)(407.17K)10.82M14.72M
Effect of Forex Changes16.9K19.39K(25.25K)(54.7K)(13.43K)
Net Change in Cash36.2M(19.25M)(16.27M)1.21M8.78M
Free Cash Flow(13.08M)(19.12M)(15.84M)(9.56M)(5.93M)

MiNK Therapeutics, Inc.

NASDAQ:INKT

Intrinsic Alpha fair value

Locked

Current Price

$10.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.